Danaher (NYSE:DHR) Price Target Increased to $265.00 by Analysts at Stifel Nicolaus

Danaher (NYSE:DHR) had its price target hoisted by Stifel Nicolaus from $250.00 to $265.00 in a research report released on Wednesday, Benzinga reports. Stifel Nicolaus currently has a hold rating on the conglomerate’s stock.

Other equities research analysts have also recently issued research reports about the company. Bank of America boosted their price objective on Danaher from $270.00 to $275.00 and gave the company a “neutral” rating in a research note on Wednesday, July 24th. Wells Fargo & Company initiated coverage on shares of Danaher in a research note on Tuesday, August 27th. They set an “equal weight” rating and a $280.00 price target for the company. TD Cowen raised their price objective on shares of Danaher from $290.00 to $310.00 and gave the stock a “buy” rating in a research report on Wednesday, July 24th. Leerink Partners upped their target price on shares of Danaher from $275.00 to $280.00 and gave the company an “outperform” rating in a report on Wednesday, July 24th. Finally, The Goldman Sachs Group boosted their price target on Danaher from $225.00 to $250.00 and gave the company a “neutral” rating in a research report on Wednesday, July 24th. Seven investment analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $287.28.

Danaher Trading Down 2.0 %

NYSE DHR opened at $256.00 on Wednesday. The firm’s fifty day moving average price is $270.43 and its 200 day moving average price is $260.43. Danaher has a 12 month low of $182.09 and a 12 month high of $281.70. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.43 and a quick ratio of 1.04. The company has a market capitalization of $189.62 billion, a price-to-earnings ratio of 43.39, a price-to-earnings-growth ratio of 4.49 and a beta of 0.83.

Danaher (NYSE:DHR) last issued its quarterly earnings data on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.57 by $0.14. Danaher had a return on equity of 11.06% and a net margin of 16.94%. The company had revenue of $5.80 billion for the quarter, compared to analyst estimates of $5.59 billion. During the same quarter last year, the company posted $2.02 earnings per share. The business’s quarterly revenue was up 3.1% compared to the same quarter last year. On average, sell-side analysts expect that Danaher will post 7.59 earnings per share for the current fiscal year.

Danaher Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, October 25th. Stockholders of record on Friday, September 27th will be issued a $0.27 dividend. The ex-dividend date of this dividend is Friday, September 27th. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.42%. Danaher’s dividend payout ratio is presently 18.31%.

Insider Activity at Danaher

In other Danaher news, SVP Georgeann Couchara sold 952 shares of the company’s stock in a transaction dated Monday, August 26th. The shares were sold at an average price of $268.37, for a total transaction of $255,488.24. Following the transaction, the senior vice president now directly owns 4,212 shares in the company, valued at approximately $1,130,374.44. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. In other news, CEO Rainer Blair sold 9,007 shares of Danaher stock in a transaction on Wednesday, July 31st. The stock was sold at an average price of $280.00, for a total transaction of $2,521,960.00. Following the completion of the transaction, the chief executive officer now owns 97,983 shares of the company’s stock, valued at $27,435,240. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, SVP Georgeann Couchara sold 952 shares of the stock in a transaction dated Monday, August 26th. The shares were sold at an average price of $268.37, for a total transaction of $255,488.24. Following the completion of the sale, the senior vice president now directly owns 4,212 shares in the company, valued at approximately $1,130,374.44. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 30,059 shares of company stock worth $8,400,897 over the last 90 days. Company insiders own 11.10% of the company’s stock.

Institutional Trading of Danaher

Several large investors have recently modified their holdings of DHR. Good Life Advisors LLC purchased a new stake in Danaher in the 3rd quarter valued at approximately $217,000. Oak Thistle LLC acquired a new stake in shares of Danaher during the second quarter valued at $363,000. Norden Group LLC acquired a new position in Danaher in the 1st quarter valued at about $4,151,000. Duality Advisers LP purchased a new position in Danaher in the 1st quarter valued at about $5,573,000. Finally, Investment Research & Advisory Group Inc. acquired a new stake in shares of Danaher during the 1st quarter worth about $1,186,000. 79.05% of the stock is currently owned by institutional investors and hedge funds.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.